Specialty Pharma Journal Specialty, Precision & Technology
New research findings published in the Journal of Leukocyte Biology, suggest that synovial CD4+ T cells that produce IL-21 contribute to joint inflammation by activating synovial fibroblasts in rheumatoid arthritis patients. Understanding the mechanisms of inflammation in rheumatoid arthritis is important for the design of new therapies for this disease. …
Tag Archives: American College of Rheumatology
March, 2017
November, 2016
-
14 November
Celltrion Presents New Data Supporting Efficacy and Safety of its Biosimilars
WASHINGTON–(BUSINESS WIRE)–New data presented today at the 2016 American College of Rheumatology (ACR) Annual Meeting demonstrate that the efficacy and safety profile of CT-P10 (biosimilar rituximab) in rheumatoid arthritis (RA) patients is comparable to patients treated with originator rituximab over 24 weeks.1,2 A total of 372 RA patients (161 patients …
July, 2016
-
1 July
Rheumatology Providers, FDA Leaders Discuss Biosimilar Policy Challenges & Opportunities at National Policy Briefing
WASHINGTON, DC – Experts from the American College of Rheumatology (ACR), Food and Drug Administration (FDA), and other leading national healthcare groups spoke about the emerging biosimilars market, including key policy and regulatory questions for patients, providers and the healthcare system, during a national policy briefing held today by the …
April, 2015
-
22 April
Even After the Introduction of Biosimilars in the US, RA Patients May Still Face High Cost Burden
An investigation of Medicare coverage of biologic disease modifying drugs (DMARDs) found that starting these drugs can cost Medicare patients more than $2,700 in co-payments a year, and patients may continue to face a high cost burden even with the introduction of biosimilars. Results from a new study, published in …